Table 1. Demographics for each study component.
Age at time of study, BMI, past history of Major Depressive Episode (MDE), PMDD treatment history, and parity (which refers to the number of times a woman has carried a pregnancy to a viable gestational age) of the subjects chosen for cell line generation. qRT-PCR for Hormone Receptors: Demographics of the 15 Control women and 15 PMDD women chosen (subset from Groups 3 and 4) to complete qRT-PCR analysis of the four hormone receptors. No significant differences in age (t28=0.7, p=0.5) or BMI (t28=0.0, p>0.99) between groups. RNAseq for untreated conditions and hormone exposure (and protein): Demographics of the 9 Control women and 10 PMDD women chosen (from Groups 1 and 2) to complete RNA-sequencing studies of untreated or hormone-treated cell lines as well as all protein analyses. No significant differences in age (t17=1.3, p=0.2) or BMI (t17=0.2, p=0.8) between groups. qRT-PCR replication: Demographics of the 24 control women and 24 PMDD women chosen (Groups 3 and 4) to complete the replication/validation study of mRNA expression in untreated cell lines for the 13 ESC/E(Z) genes. No significant differences in BMI (t35=1.39, p=0.173) between groups, though Age was significantly different (t46=4.4, p<0.0001).
| From Groups 3 and 4 – used in qRTPCR for Hormone Receptors | |||||||||
| Diagnosis | N | Ethnicity |
Agea (years) |
BMIa (kg/m2) |
Past History of MDEb |
Past PMDD Treatment Historyb |
Parityc | ||
| Control | 15 | Caucasian (10) African American (3) Asian (2) |
39.7(6.6) | 25.1(6.7) 1 missing |
0 (0%) | NA | 10 (1–3) | ||
| PMDD | 15 | Caucasian (10) African American (5) |
38.0(6.7) | 25.1(4.9) 2 missing |
6 (40%) | Anti-depressants 3 (20%) |
8 (1–5) | ||
| Groups 1 and 2 – used in RNAseq for untreated and hormone exposures (and protein) | |||||||||
| Diagnosis | N | Ethnicity |
Agea (years) |
BMIa (kg/m2) |
Past History of MDEb |
Past PMDD Treatment Historyb |
Parityc |
Age of onset of PMDDa (years) |
Duration of PMDDa (years) |
| Control | 9 | Caucasian (4) African American (5) |
36.9(6.5) | 27.8(7.4) | 0 (0%) | NA | 4 (2–3) | NA | NA |
| PMDD | 10 | Caucasian (6) African American (4) |
40.6(5.7) | 27.2(4.6) | 4 (40%) | Anti-depressants 3 (30%) |
8 (1–5) | 27.9(10.5) | 12.7(8.4) |
| Groups 3 and 4 – used in qRTPCR replication | |||||||||
| Diagnosis | N | Ethnicity |
Agea (years)* |
BMIa (kg/m2) |
Past History of MDEb |
Past PMDD Treatment Historyb |
Parityc | ||
| Control | 24 | Caucasian (15) African American (6) Asian (2) Hispanic (1) |
29.9(7.2) | 23.9(5.1) 4 missing |
0 (0%) | NAd | 6 (1–3) | ||
| PMDD | 24 | Caucasian (17) African American (7) |
37.9(5.3) | 26.2(5.1) 7 missing |
6 (25%) | Anti-depressants 3 (12.5%) Supplements 1 (4.1%) |
12 (1–3) | ||
numbers listed as mean(standard deviation)
numbers listed as number(percentage) – All women in this study were medication free. Medication use in the past (i.e., prior to enrollment in the clinical studies) is listed in the Past PMDD Treatment History column for each group. Anti-depressants include Prozac, SSRI, and Zoloft; Supplement is EPO
numbers listed as number of parous women (range of number of live births)
note one Control subject has a history of Effexor treatment
significant difference between Control and PMDD (students t-test, p<0.05)